Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Neuregulin 1: genetic support for schizophrenia subtypes

Neuregulin 1: genetic support for schizophrenia subtypes Scientific Correspondence interesting for studies on the pathophysiology and phar- Assessment of Symptoms and History and informa- macological treatment of DRD2-associated neurological tion from medical records. The Schedule for the Deficit and psychiatric disorders, for example, Parkinson’s Syndrome (SDS) was completed for 260 patients disease, schizophrenia and alcoholism. DRD2 is a (92.2%), 130 of whom met deficit criteria. In 29 patients major target of antipsychotic drugs and further studies with severe negative symptoms, it could not be ruled on the significance of C957T polymorphism in the out that these symptoms were secondary to factors such antipsychotic drug response is warranted. as substance abuse. Following the SDS, they were classified as nondeficit schizophrenia. The Medical 1,2 2 2 2 Ethical Committee of the UMC Utrecht approved the M Hirvonen , A Laakso ,K Na˚gren , JO Rinne , 1 2,3 study and all patients gave written informed consent. T Pohjalainen and J Hietala 1 The control panel (n¼ 585) consisted of 472 DNA Department of Pharmacology and Clinical Pharmacology, 2 samples from random Dutch individuals, obtained from University of Turku, Turku, Finland; Turku PET Centre, the Immunogenetics and Transplantation Immunology Turku University Central Hospital, Turku, Finland; 3 Section of the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Molecular Psychiatry Springer Journals

Neuregulin 1: genetic support for schizophrenia subtypes

Download PDF
3 pages

Loading next page...
 
/lp/springer-journals/neuregulin-1-genetic-support-for-schizophrenia-subtypes-dmS3FDKYgk

References (13)

Publisher
Springer Journals
Copyright
Copyright © 2004 by Nature Publishing Group
Subject
Medicine & Public Health; Medicine/Public Health, general; Psychiatry; Neurosciences; Behavioral Sciences; Pharmacotherapy; Biological Psychology
ISSN
1359-4184
eISSN
1476-5578
DOI
10.1038/sj.mp.4001564
Publisher site
See Article on Publisher Site

Abstract

Scientific Correspondence interesting for studies on the pathophysiology and phar- Assessment of Symptoms and History and informa- macological treatment of DRD2-associated neurological tion from medical records. The Schedule for the Deficit and psychiatric disorders, for example, Parkinson’s Syndrome (SDS) was completed for 260 patients disease, schizophrenia and alcoholism. DRD2 is a (92.2%), 130 of whom met deficit criteria. In 29 patients major target of antipsychotic drugs and further studies with severe negative symptoms, it could not be ruled on the significance of C957T polymorphism in the out that these symptoms were secondary to factors such antipsychotic drug response is warranted. as substance abuse. Following the SDS, they were classified as nondeficit schizophrenia. The Medical 1,2 2 2 2 Ethical Committee of the UMC Utrecht approved the M Hirvonen , A Laakso ,K Na˚gren , JO Rinne , 1 2,3 study and all patients gave written informed consent. T Pohjalainen and J Hietala 1 The control panel (n¼ 585) consisted of 472 DNA Department of Pharmacology and Clinical Pharmacology, 2 samples from random Dutch individuals, obtained from University of Turku, Turku, Finland; Turku PET Centre, the Immunogenetics and Transplantation Immunology Turku University Central Hospital, Turku, Finland; 3 Section of the

Journal

Molecular Psychiatry – Springer Journals

Published: Aug 10, 2004

There are no references for this article.